Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $13.00 Consensus PT from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.00.

A number of analysts have weighed in on CMPX shares. Leerink Partners raised Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Citizens Jmp set a $10.00 price target on Compass Therapeutics in a research note on Wednesday, December 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Compass Therapeutics in a report on Thursday, March 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Finally, D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, January 6th.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $5.15 on Wednesday. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The stock has a market capitalization of $927.46 million, a price-to-earnings ratio of -11.98 and a beta of 1.48. The company has a 50-day simple moving average of $5.92 and a 200-day simple moving average of $4.97.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. As a group, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares in the last quarter. Creative Planning acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $30,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at approximately $32,000. Strs Ohio purchased a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $34,000. Finally, Apollon Wealth Management LLC acquired a new position in Compass Therapeutics during the third quarter worth $35,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.